Currently holds positions in Adaptimmune Therapeutics PLC, Medimmune LLC and Ardelyx Inc
Position | Company | Period |
---|---|---|
Chief Operating Officer | Adaptimmune Therapeutics PLC | March 15, 2017 - |
Executive Vice President, General Counsel | Medimmune LLC | None - |
Independent Director | Ardelyx Inc | Oct. 26, 2015 - |
Executive Vice President, General Counsel | Infinity Pharmaceuticals Inc | Oct. 19, 2015 - Sept. 2, 2016 |
Acting Chief Operating Officer | Salix Pharmaceuticals Ltd | Jan. 30, 2015 - April 1, 2015 |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Value | Details | |
---|---|---|---|---|---|---|---|---|
2024-01-17 | 2024-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
13,599
-40.2%
0.67USD 9,152 |
13,599 -40.2% | 0.67 | USD 9,152 | |
2024-01-17 | 2024-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
5,309
-40.5%
0.67USD 3,573 |
5,309 -40.5% | 0.67 | USD 3,573 | |
2024-01-17 | 2024-01-16 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,681
-40.0%
0.79USD 3,698 |
4,681 -40.0% | 0.79 | USD 3,698 | |
2024-01-12 | 2024-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
5,220
-39.9%
0.85USD 4,458 |
5,220 -39.9% | 0.85 | USD 4,458 | |
2024-01-12 | 2024-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,009
-39.6%
0.84USD 3,354 |
4,009 -39.6% | 0.84 | USD 3,354 | |
2023-01-17 | 2023-01-17 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,440
-37.9%
1.86USD 8,250 |
4,440 -37.9% | 1.86 | USD 8,250 | |
2023-01-12 | 2023-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,973
-38.0%
1.71USD 8,484 |
4,973 -38.0% | 1.71 | USD 8,484 | |
2023-01-12 | 2023-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,843
-38.0%
1.75USD 6,713 |
3,843 -38.0% | 1.75 | USD 6,713 | |
2023-01-04 | 2023-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,584
-38.3%
1.69USD 6,071 |
3,584 -38.3% | 1.69 | USD 6,071 | |
2022-01-18 | 2022-01-18 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
4,368
-37.3%
3.19USD 13,942 |
4,368 -37.3% | 3.19 | USD 13,942 | |
2022-01-13 | 2022-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,248
-37.5%
3.54USD 7,967 |
2,248 -37.5% | 3.54 | USD 7,967 | |
2022-01-13 | 2022-01-11 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,770
-37.3%
3.56USD 13,409 |
3,770 -37.3% | 3.56 | USD 13,409 | |
2022-01-05 | 2022-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,490
-37.3%
4.06USD 14,184 |
3,490 -37.3% | 4.06 | USD 14,184 | |
2021-01-12 | 2021-01-12 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,234
-37.2%
6.15USD 13,744 |
2,234 -37.2% | 6.15 | USD 13,744 | |
2021-01-05 | 2021-01-04 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,499
-37.4%
5.33USD 18,642 |
3,499 -37.4% | 5.33 | USD 18,642 | |
2020-12-15 | 2020-12-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
B Purchase |
207,000
+266.0%
0.69USD 143,824 |
207,000 +266.0% | 0.69 | USD 143,824 | |
2020-01-15 | 2020-01-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,397
-39.9%
5.13USD 12,308 |
2,397 -39.9% | 5.13 | USD 12,308 | |
2020-01-07 | 2020-01-06 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
3,731
-39.8%
1.20USD 4,477 |
3,731 -39.8% | 1.20 | USD 4,477 | |
2019-01-16 | 2019-01-14 |
Adaptimmune Therapeutics PLC
(ADAP)
|
S Sale |
2,271
-37.8%
5.37USD 12,194 |
2,271 -37.8% | 5.37 | USD 12,194 |
// ... existing code ... // ... rest of the file ...